Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Crosses Below Two Hundred Day Moving Average of $7.47

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $7.47 and traded as low as $4.57. Eagle Pharmaceuticals shares last traded at $4.69, with a volume of 161,336 shares traded.

Eagle Pharmaceuticals Price Performance

The firm has a 50-day moving average price of $5.56 and a two-hundred day moving average price of $7.47. The company has a market capitalization of $60.92 million, a price-to-earnings ratio of 3.97 and a beta of 0.41.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. boosted its position in Eagle Pharmaceuticals by 25.0% during the third quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the specialty pharmaceutical company’s stock valued at $7,885,000 after purchasing an additional 100,000 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in Eagle Pharmaceuticals during the third quarter valued at approximately $575,000. Brandes Investment Partners LP boosted its position in Eagle Pharmaceuticals by 34.9% during the third quarter. Brandes Investment Partners LP now owns 1,134,363 shares of the specialty pharmaceutical company’s stock valued at $17,889,000 after purchasing an additional 293,276 shares during the last quarter. Trexquant Investment LP boosted its position in Eagle Pharmaceuticals by 26.1% during the third quarter. Trexquant Investment LP now owns 67,187 shares of the specialty pharmaceutical company’s stock valued at $1,060,000 after purchasing an additional 13,910 shares during the last quarter. Finally, Strs Ohio acquired a new position in Eagle Pharmaceuticals during the third quarter valued at approximately $145,000. 85.36% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.